Avalo Therapeutics AVTX
NASDAQ AVTX
$12.26 -0.10 (-0.81%)
At close: Oct 21, 2026 · 4:00 PM EDT

Avalo Therapeutics (AVTX) Notes Payables (2022 - 2023)

Updated

Avalo Therapeutics' Notes Payables came in at $14.12 million for Q2 2023, up 51.8% from the prior quarter.

Analysis

Avalo Therapeutics (AVTX) Notes Payables (2022 - 2023) Analysis & Trends

At the end of FY2022, Avalo Therapeutics' Notes Payables was $5.93 million.

  • Business Quant data shows AVTX's Notes Payables at $9.3 million (Q1 2023), $5.93 million (Q4 2022) and $2.56 million (Q3 2022) in the three quarters before Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Avalo Therapeutics 533.82 Mn -158.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 14.12 Mn
Mar 31, 2023 9.30 Mn
Dec 31, 2022 5.93 Mn
Sep 30, 2022 2.56 Mn
API Access

Avalo Therapeutics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=AVTX&period=max&api_key=YOUR_API_KEY